Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q1 2019 · 10-Q
Revenue$31.60M$31.60M+173.2% vs Q1 2018 Net Income-$63.01M-$63.01MN/M vs Q1 2018 EPS Diluted-$0.80-$0.80N/M vs Q1 2018 Gross Profit$16,640,000+97.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Operating Cash Flow-$49,024,000N/M Free Cash Flowderived-$51,160,000N/M Margins · derivedGross margin52.7%−20.3 pt vs Q1 2018
Operating margin-204.7%+244.7 pt vs Q1 2018
Net margin-199.4%+252.5 pt vs Q1 2018
ended Mar 31, 2019 · filed May 9, 2019 · 39 d after period end